Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.

Mol Ther Oncolytics · 2022 · PMC8971678 · PMID 35399603

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Compared with the number at baseline, the number of IFN-γ + spots generated from CD8 + T cells on day 14 after H101 treatment showed an increasing trend, indicating a tumor-specific immune response is likely activated by H101 ( Figure 4 C).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.